Growth Hormone Promotes Hepatic Triglyceride Export in Humans
Authors' conclusion
GH modulates hepatic lipid turnover via an increase in hepatic triglyceride export and repressed GH action tends to foster DNL, which may be of assistance for the development of future therapeutic strategies against metabolic dysfunction-associated steatotic liver disease.
Study context
- Population
- Healthy male volunteers (26 ± 5 years, BMI 23 ± 3.4 kg/m²); comparison patients with active acromegalycrossover
- Participants
- 10 volunteers
- Comparison
- Growth hormone (GH) vs GH-receptor antagonist, each assessed before and after 1 week; comparison with patients with active acromegaly
- Outcome
- VLDL-triglyceride secretion
- Follow-up
- After 1 week
Methodological detailscrossover, 1-week daily subcutaneous treatment
- Crossover
- 1-week daily subcutaneous treatment
Main finding
As reported in the abstract
GH treatment stimulated very low-density lipoprotein (VLDL)-triglyceride secretion (590.5 ± 282.3 vs 738.8 ± 424.9 mg/h), P = .035
26.1%
Further findings
De novo lipogenesis · after 1 week
- Mean de novo lipogenesis (DNL) doubled after GH-receptor blockade, not statistically significant (3.06 ± 1.95 vs 7.32 ± 8.43%), P = .107
Hepatic ATP synthesis
- No effects on hepatic ATP synthesis observed
Baseline hepatic VLDL secretion, volunteers vs acromegaly
- Comparable between volunteers and patients with acromegaly
Original publication
Growth Hormone Promotes Hepatic Triglyceride Export in Humans. J Clin Endocrinol Metab. Published 11 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →